The quest for convenient drug delivery has taken a significant step forward with a modern partnership between pharmaceutical giant Novo Nordisk and biotechnology firm Vivtex. The collaboration, announced February 26, 2026, focuses on developing innovative oral formulations for biologic drugs – a class of medications currently administered primarily via injection. This initiative aims to improve patient compliance and access to treatments for conditions like obesity and diabetes, and related metabolic comorbidities.
The agreement will see Vivtex license its proprietary oral drug-delivery technologies to Novo Nordisk. In return, Vivtex is poised to receive substantial financial backing, including research funding, upfront payments, and potential milestone payments totaling up to $2.1 billion, alongside tiered royalties on future product sales. This substantial investment underscores the potential of oral biologics to revolutionize treatment paradigms.
The Challenge of Oral Biologics
Biologic drugs, derived from living organisms, offer targeted and often highly effective treatments for a range of complex diseases. However, their large molecular size and inherent instability pose significant challenges to oral administration. As detailed in a 2025 review published in Wiley-VCH GmbH, the gastrointestinal tract presents a harsh environment for these delicate molecules. Low pH levels, enzymatic degradation, and limited permeability of the intestinal epithelium all contribute to poor bioavailability – meaning a minor percentage of the drug actually reaches the bloodstream. Here’s why biologics are typically administered via injection, a method that bypasses these digestive barriers.
Researchers have been actively exploring strategies to overcome these hurdles. According to a study published in PubMed, potential solutions include nanoparticle-delivery systems, ionic liquids, and microneedles. Colon-targeted approaches are also being investigated, as the colon offers a potentially more favorable environment for absorption due to reduced enzymatic activity. Vivtex’s platform appears to address these challenges directly, offering a systematic approach to optimizing oral delivery.
Vivtex’s Technology and Novo Nordisk’s Expertise
Vivtex’s approach centers around integrating drug-delivery technologies, advanced gastrointestinal screening assays, artificial intelligence (AI) tools, and computational simulation. This integrated platform is designed to identify formulations that maximize oral bioavailability and ensure consistent performance in humans. The company was founded specifically to tackle the complexities of delivering biologics orally, employing a data-driven approach to systematically solve the problem.
Novo Nordisk brings to the table decades of experience in peptide and protein engineering, including a track record of innovation in oral peptide formulation. Brian Vandahl, Senior Vice President of Therapeutics Discovery at Novo Nordisk, highlighted the company’s pioneering work in this field, noting that they launched the first-ever oral biologic over five years ago and recently introduced the world’s first oral biologic for obesity. This demonstrates a clear commitment to expanding treatment options beyond traditional injections.
A Growing Market for Oral Biologics
The potential benefits of oral biologics extend beyond improved patient convenience. Increased adherence to treatment regimens, reduced healthcare costs, and broader accessibility are all potential advantages. The success of Novo Nordisk’s existing oral biologics suggests a growing market demand for these types of therapies. The company’s continued investment in this area, through both internal research and external partnerships like the one with Vivtex, reflects this optimistic outlook.
Thomas von Erlach, CEO and co-founder of Vivtex, emphasized the transformative potential of their collaboration. “Partnering with Novo Nordisk allows us to apply our platform across important metabolic disease areas, with the goal of enabling oral therapies that would otherwise require injection,” he stated. This collaboration aims to unlock new possibilities for treating millions of people affected by obesity, diabetes, and related conditions.
Recent Partnerships and Future Directions
Novo Nordisk’s commitment to innovation extends beyond the Vivtex partnership. Last month, the company announced a new phase in its ongoing collaboration with Aspect Biosystems, focusing on the development of curative cellular medicines for diabetes, as reported by Pharmaceutical Technology. This demonstrates a broader strategy of investing in cutting-edge technologies to address unmet medical needs.
The partnership with Vivtex specifically targets metabolic diseases, but the underlying technology could potentially be applied to a wider range of therapeutic areas. The success of this collaboration could pave the way for oral formulations of biologics used to treat autoimmune diseases, cancer, and other complex conditions. The development process will involve rigorous research, formulation selection, and clinical trials, with Novo Nordisk ultimately responsible for global development, regulatory approvals, manufacturing, and commercialization of any successful products.
Key Takeaways
- Novo Nordisk and Vivtex have partnered to develop oral formulations of biologic drugs.
- Vivtex could receive up to $2.1 billion in milestone payments and royalties.
- Oral biologics face challenges related to gastrointestinal degradation and absorption.
- The collaboration leverages Vivtex’s technology and Novo Nordisk’s expertise in peptide and protein engineering.
- This partnership aims to improve patient convenience and access to treatments for obesity, diabetes, and related conditions.
The next steps for Novo Nordisk and Vivtex will involve intensive research and development efforts to identify promising drug candidates and optimize their oral bioavailability. The timeline for bringing these therapies to market remains uncertain, but the potential impact on patient care is significant. The progress of this collaboration will be closely watched by the pharmaceutical industry and the medical community alike.
What are your thoughts on the potential of oral biologics? Share your comments below, and let’s continue the conversation.
Keep reading